Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification

NCT03253679 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03253679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03253679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
January 16, 2019
Completion date
October 31, 2022
Enrollment
31 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, refractory malignant solid neoplasm